TMS for Bipolar II Disorder: Evidence-Based Recommendations
TMS shows promise for bipolar II depression with high remission rates (78% at 1-month follow-up) using modified protocols, though the overall evidence base remains limited and individual trial results are inconsistent. 1
Current Evidence Quality and Limitations
The evidence for TMS in bipolar II disorder specifically is sparse compared to unipolar depression. The most recent comprehensive meta-analysis (2026) examining TMS for bipolar depression found only a small antidepressant effect (SMD = -0.34), and critically, 88.2% of individual trials failed to show superiority over sham at the individual study level 2. This meta-analysis included both bipolar I (41.8%) and bipolar II (58.2%) patients, with most studies having "some concerns" regarding risk of bias (65%).
Protocol Considerations for Bipolar II
Modified Protocol Shows Superior Results
The most compelling evidence for bipolar II specifically comes from a 2022 open-label study using a reduced-pulse protocol: 1000 pulses per session for 20 consecutive working days (20,000 total pulses over 4 weeks), achieving 78% remission at 1-month follow-up 1. This contrasts with standard protocols using higher pulse numbers.
Key findings from this protocol:
- 26% remission after 10 sessions
- 61% remission after 20 sessions
- 78% remission at 1-month follow-up
- No adverse effects reported
- Highly tolerable in this population
Standard High-Frequency Protocols
A 2024 pilot study using standard 10 Hz left dorsolateral prefrontal cortex (DLPFC) stimulation (3,000 pulses/session, 120% motor threshold) showed 87.1% response and 74.2% remission rates in bipolar depression 3. However, this study combined bipolar I and II patients and lacked a control group.
Target Selection
Left DLPFC remains the most common and evidence-supported target (used in 12 of 19 comparisons in the meta-analysis) 2. A 2024 randomized controlled trial comparing right ventrolateral versus left dorsolateral 10 Hz stimulation found neither achieved statistical significance over sham, though both showed numerical trends toward improvement 4.
Recent evidence suggests theta burst stimulation (TBS) may offer advantages for maintenance treatment, with one case report documenting resolution of brain fog and reduced hypomanic/depressive episodes using 10 sessions of TBS (3.5 minutes each, 20 trains, 10 bursts) 5.
Critical Safety Considerations
TMS appears safe in bipolar II disorder with no seizures or serious adverse events reported across studies 2. Importantly:
- All patients must be concurrently treated with mood stabilizers to prevent manic switching 3
- Lamotrigine co-treatment was associated with better outcomes (lower depression scores) 3
- Lithium co-treatment was associated with higher depression scores throughout treatment 3
- No manic conversions were reported when proper mood stabilizer coverage was maintained
Dose-Response Relationship
Meta-regression analysis revealed that higher total pulse numbers correlate with greater depressive symptom reduction (β = -0.018; p = 0.00017) 2. This creates a paradox with the bipolar II-specific study showing excellent results with lower pulse numbers 1, suggesting bipolar II may respond differently than bipolar I or require different optimization strategies.
Clinical Algorithm
For bipolar II depression resistant to medication:
- Ensure mood stabilizer coverage (preferably lamotrigine based on outcome data)
- Consider modified protocol: 1000 pulses/session × 20 sessions over 4 weeks targeting left DLPFC 1
- Alternative: Standard 10 Hz protocol (3000 pulses/session, 120% motor threshold) if modified protocol unavailable 3
- Assess response at 10 sessions - if inadequate, continue to 20 sessions
- Plan 1-month follow-up as improvement may continue post-treatment 1
- Consider TBS maintenance sessions if initial response achieved 5
Important Caveats
- Most individual RCTs are negative despite positive meta-analytic pooling, indicating high heterogeneity in treatment response 2
- Subgroup analyses by treatment resistance, TMS type, and stimulation site did not consistently confirm efficacy 2
- Evidence is strongest for open-label studies; blinded RCTs show more modest effects 2, 4
- Bipolar II-specific data is extremely limited - most studies combine bipolar I and II or don't specify subtypes
- The field urgently needs larger, well-powered RCTs with standardized protocols and longer follow-up 1, 2
Personalization Factors
Emerging evidence suggests response may be enhanced by:
- Lower left frontal cortex volume predicts better response 6
- MRI-guided neuronavigation for precise targeting 7, 6
- Connectivity-guided targeting may improve outcomes, especially for cognitive symptoms 6
- Older age may reduce response 3
Given the limited but encouraging evidence, TMS represents a reasonable treatment option for medication-resistant bipolar II depression when used with appropriate mood stabilizer coverage, though patients should be counseled about the inconsistent evidence base and need for further research.